A Clinical Outcomes Study to Evaluate the Effects of IL-6 Receptor Blockade With Tocilizumab (TCZ) in Comparison With Etanercept (ETA) on the Rate of Cardiovascular Events in Patients With Moderate to Severe Rheumatoid Arthritis (RA)
A Clinical Outcomes Study to Evaluate the Effects of IL-6 Receptor Blockade With Tocilizumab (TCZ) in Comparison With Etanercept (ETA) on the Rate of Cardiovascular Events in Patients With Moderate to Severe Rheumatoid Arthritis (RA)
This randomized, open-label, parallel-group, multicenter study will evaluate the rate of cardiovascular events with tocilizumab in comparison to etanercept in participants with rheumatoid arthritis (RA). Participants will be randomized to receive intravenous (IV) 8 milligrams per kilogram (mg/kg) tocilizumab every 4 weeks or subcutaneous 50 milligrams (mg) etanercept weekly, with or without non-biologic disease-modifying anti-rheumatic drug (DMARD).
Inclusion Criteria:
Exclusion Criteria:
Colorado Springs, Colorado 80920, United States
Pittsburgh, Pennsylvania 15213-2582, United States
Wyomissing, Pennsylvania 19610, United States
Ciudad Autonoma Buenos Aires, C1221ADC, Argentina
Ciudad Autonoma Buenos Aires, C1284AEB, Argentina
Cordoba Pcia, 5016, Argentina
Rosario, Santa Fe, S2000PBJ, Argentina
Rijeka, 51000, Croatia
Ostrava - Moravska Ostrava, 702 00, Czechia
Hamburg, 20251, Germany
Crete, 71110, Greece
Budapest, 1027, Hungary
Banglore, 560034, India
Beer Yaacov, 6093000, Israel
Telese Terme, Campania 82037, Italy
Milan, Lombardy 20162, Italy
Culiacán, Sinaloa 80000, Mexico
Delegacion Benito Juarez, 03100, Mexico
Miexico City, 06700, Mexico
San Luis Potosi S.l.p., 78240, Mexico
San Luis Potosí City, 78200, Mexico
Krakow, 30-119, Poland
Szczecin, 71-252, Poland
Cluj-Napoca, 400349, Romania
S. Cristobal de La Laguna, Tenerife 38320, Spain
Westcliffe-on-sea, SS0 0RY, United Kingdom